Skip to content

Mapping the Lumbar Spine Marrow Adiposity

Mapping the Lumbar Spine Marrow Adiposity

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02887716
Acronym
FATFRAC
Enrollment
50
Registered
2016-09-02
Start date
2015-08-31
Completion date
2015-11-30
Last updated
2016-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marrow Adiposity Lumbar Spine

Brief summary

The objective of this study is to describe the change in the percentage of fat in the lumbar spine.

Detailed description

The study of the distribution of bone marrow adiposity is little known in subjects who did not have pathology likely to alter the fat content of the vertebrae. Or that fat content is potentially a reflection of brittle bones (osteoporosis, for example), and deserves to be known because it can be used to normalize the lipid fraction values with respect to age or from the level (L1 , L2, L3, L4 or L5) of the vertebra being studied.

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consecutive patients who underwent MRI of the lumbar spine with Sagittal sequenceT1, T2 STIR and IDEAL, good quality, in a clinical setting type back pain, spondylitis research, radicular syndrome ... * Examinations conducted between 2014 and 2015 on the same equipment * Major patient * Having formulated their non-opposition

Exclusion criteria

* Previous history of neoplastic disease * Vertebral Fracture * Pathology reaching the vertebral body detectable by MRI (disc lesion with rearrangements of the endplates (MODIC) * Inflammation, * Bone tumor, * fracture * Refusal of participation

Design outcomes

Primary

MeasureTime frame
Value of the fat fraction by vertebral level of the lumbar spine, in MRI, measured on the mapping generated by the IDEAL-IQ sequence.3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026